Share this video  

ESMO 2022 | Prognostic biomarkers for prostate cancer

Fred Saad, MD, FRCS, University of Montreal Hospital Center, Montreal, Canada, discusses prognostic biomarkers for prostate cancer, the most common being volume of metastatic disease, site of metastatic disease and the presence of visceral metastases. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.